Tag: Hemophilia b

In the United States, hemophilia is estimated to affect between 30,000 and 33,000 males [1.9.1]. The question, 'What is the drug of choice for hemophilia?' does not have a single answer, as treatment is highly individualized based on the type, severity, and patient-specific factors.

Epistaxis (nosebleeds) are a common occurrence, with studies showing that in some pediatric hemophilia populations, they can affect up to 66% of patients with moderate hemophilia A [1.9.3]. Understanding **how do you treat hemophilia nosebleeds** effectively is crucial for patient safety.

As of late 2024 and into 2025, the one-time gene therapy Lenmeldy (atidarsagene autotemcel) for metachromatic leukodystrophy holds the title of the most expensive infusion drug, with a staggering list price of $4.25 million. This represents a new peak in the rapidly evolving landscape of ultra-high-cost pharmaceuticals, dominated by groundbreaking gene therapies for rare genetic diseases.

FEIBA is a sterile, freeze-dried human plasma fraction manufactured from large pools of human plasma. This article delves into the key question: what is FEIBA made of and how do its components work to control bleeding in patients with hemophilia and inhibitors?

The term "9 injection" is a general and unofficial phrase that does not refer to a single, specific medication. Instead, it is commonly used by patients and healthcare professionals as a shorthand for several different, potent injectable medications, including treatments for blood disorders, reproductive health, and disease prevention. Understanding the context of the **what is the main 9 injection used for?** question is key to identifying the correct treatment.

In clinical trials, Feiba was effective in managing 88% to 93% of bleeding episodes in patients with hemophilia and inhibitors. **What is Feiba?** It is an Anti-Inhibitor Coagulant Complex used to control and prevent bleeding in these specific patient populations.